Navigation Links
Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases

Additional data to be published in an upcoming issue of Anti-Cancer Drugs

VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox's PRX 302. The Journal of the National Cancer Institute ("JNCI") has published the work conducted by Dr. Sam Denmeade and his team at Johns Hopkins University in collaboration with Protox scientists. The paper describes the Company's compound, PRX302, which is a prostate specific antigen (PSA) activated pro-drug being developed for the treatment of prostate cancer and BPH.

"Having results of our PRX302 research program published in a prestigious journal such as JNCI is a testament to the importance of advancing PRX302 for prostate cancer and BPH," stated Dr. Fahar Merchant, President and CEO of Protox. "The published results are consistent with the encouraging interim data from the ongoing Phase I prostate cancer trial reported earlier this year and supports the planned Phase I BPH clinical trial which we expect to commence in Q2 of 2007."

The major advantage of using PRX302 as a therapeutic agent for prostatic diseases is that it involves direct injection into the target tissue and selective activation by PSA produced only by the target tissue. The paper, entitled "A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease" (JNCI, Vol.99, Issue 5 pp, 376-385) found that: PRX302 direct injection into the prostate did not cause any attributable accumulation of PRX302 outside of the prostate gland; is not toxic to adjacent non-PSA producing organs and tissues; and PRX302 has a selective mechanism of action and favourable safety profile.

A second paper entitled, "Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity" is to appear in the upcoming issue of Anti-Cancer Drugs (ACD). The journal will publish the work cond ucted by Dr Arthur Frankel and his team at the Cancer Research Institute of Scott and White Memorial Hospital in collaboration with scientists at Protox and Johns Hopkins University. Key findings include: human prostate cancer cells are significantly more sensitive to PRX302 in the presence of active PSA; PRX302 was totally resistant to thrombin, matrix metalloprotease 7 (MMP-7), human kallikrein 1 (hk1) and human kallikrein 2 (hk2) activation; and among the normal cells tested, the PSA-producing prostate epithelial cells were the only normal cells that were highly sensitive to PRX302.

Both publications demonstrated that the PSA-activated strategy for PRX302 has a number of inherent advantages as a therapeutic strategy for locally recurrent prostate cancer and BPH.

About Protox

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin, and currently has three clinical programs in
development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain st atements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox' current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

-30-

/For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199, jbeesley@protoxtherapeutics.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,
mmoore@equicomgroup.com/



'"/>




Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Orthopedic Navigation Systems Market 2014 - 2025" report to ... ... to reach USD 303.7 million by 2025. Increasing geriatric population ... the demand for orthopedic navigation systems over the forecast period. ...
(Date:3/29/2017)...  Zynex (OTCQB: ZYXI), an innovative medical technology company specializing ... for pain management, stroke rehabilitation, cardiac monitoring and neurological ... 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 a.m. ... expects to file its 2016 full year financial results ... ...
(Date:3/29/2017)... York , March 29, 2017 ... published a report, which provides an exhaustive study ... the study, nearly 242 companies are functional in ... and competitive. With the leading companies, such as ... Pharma LP, focusing aggressively on various marketing strategies ...
Breaking Medicine Technology:
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... of the Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition ... in America,” a live webinar designed to help nutrition educators and students inform ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad Kawa, ... eligible individuals in the local community. , Colon cancer is the second leading ... colon cancer while it is small, confined and easier to treat. If you are ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S CLASSIC TITLE ... the official title sponsor of the Baltimore Women’s Classic, the largest all women’s 5K ... walk or run the course around the Baltimore Inner Harbor. Mercy has been the ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
Breaking Medicine News(10 mins):